Abstract | OBJECTIVE: MATERIALS AND METHODS:
ABT-751 was evaluated against 27 subcutaneously implanted xenograft models of childhood cancer including neuroblastoma [4], osteosarcoma [4], Ewing sarcoma [2] rhabdomyosarcoma [8], medulloblastoma [1] and eight kidney cancer lines (six Wilms tumors, two rhabdoid). ABT-751 was administered at 100 mg/kg P.O. on a schedule of 5 days on, 5 days off, 5 days on, repeating the cycle at 21 days. Tumor diameters were measured at 7 day intervals for a period of 12 weeks. Three measures of antitumor activity were used: (1) clinical response criteria [e.g., partial response (PR), complete response (CR), etc.]; (2) treated to control (T/C) tumor volume at day 21; and (3) a time to event measure based on the median event free survival (EFS) of treated and control lines. RESULTS: CONCLUSIONS:
|
Authors | Christopher L Morton, Edward G Favours, Kimberly S Mercer, Claire R Boltz, Jeri Carol Crumpton, Chandra Tucker, Catherine A Billups, Peter J Houghton |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 25
Issue 4
Pg. 285-95
(Aug 2007)
ISSN: 0167-6997 [Print] United States |
PMID | 17384918
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ABT751
- Antimitotic Agents
- Sulfonamides
|
Topics |
- Animals
- Antimitotic Agents
(administration & dosage, therapeutic use)
- Cell Line, Tumor
- Child
- Female
- Humans
- Mice
- Mice, SCID
- Neoplasms, Experimental
(drug therapy)
- Pediatrics
- Sulfonamides
(administration & dosage, therapeutic use)
- Xenograft Model Antitumor Assays
|